JaLCDOI 10.18926/AMO/56178
フルテキストURL 72_4_401.pdf
著者 Wada, Nozomu| Ikeda, Fusao| Mori, Chizuru| Takaguchi, Koichi| Fujioka, Shin-ichi| Kobashi, Haruhiko| Morimoto, Yoichi| Kariyama, Kazuya| Sakaguchi, Kosaku| Hashimoto, Noriaki| Moriya, Akio| Kawaguchi, Mitsuhiko| Miyatake, Hirokazu| Hagihara, Hiroaki| Kubota, Junichi| Takayama, Hiroki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Takaki, Akinobu| Iwasaki, Yoshiaki| Okada, Hiroyuki|
抄録 Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hepatitis C virus (HCV) serogroup 1 infection. We studied the efficacy of this therapy by focusing on the factors associated with sustained virological responses (SVR) including resistance-associated variants (RAVs) and mixed infection of different HCV genotypes. We enrolled 951 HCV serogroup 1-positive patients who received this combination therapy at our hospital or affiliated hospitals. The presence of RAVs in non-structural (NS) regions 3 and 5A was analyzed by direct sequencing. HCV genotypes were determined by PCR with genotype-specific primers targeting HCV core and NS5B regions. SVR was achieved in 91.1% of patients. Female sex, age > 70 years, and RAVs were significantly associated with non-SVR (p<0.01 for all). Propensity score-matching results among the patients without RAVs regarding sex, age, and fibrosis revealed that mixed HCV infection determined by HCV NS5B genotyping showed significantly lower SVR rates than 1B-mono infection (p=0.02). Female sex and RAVs were significant factors associated with treatment failure of this combination therapy for patients with HCV serogroup 1 infection. Mixed HCV infection other than 1B-mono infection would be useful for predicting treatment failure.
キーワード mixed genotype daclatasvir asunaprevir HCV serogrouping 1 infection
Amo Type Original Article
発行日 2018-08
出版物タイトル Acta Medica Okayama
72巻
4号
出版者 Okayama University Medical School
開始ページ 401
終了ページ 406
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 30140089
JaLCDOI 10.18926/AMO/53996
フルテキストURL 70_1_1.pdf
著者 Yasunaka, Tetsuya| Ikeda, Fusao| Wada, Nozomu| Morimoto, Yuki| Fujioka, Shin-ichi| Toshimori, Junichi| Kobashi, Haruhiko| Kariyama, Kazuya| Morimoto, Yoichi| Takayama, Hiroki| Seno, Tomonori| Takaguchi, Koichi| Moriya, Akio| Miyatake, Hirokazu| Okamoto, Ryoichi| Yabushita, Kazuhisa| Takaki, Akinobu| Yamamoto, Kazuhide|
抄録 Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged &#8805; 35 years, HBV DNA &#8805; 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged &#8805; 35 years with HBV DNA &#8805; 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged&#8805;35 years with HBV DNA &#8805;4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.
キーワード entecavir hepatitis B virus lamivudine hepatocellular carcinoma
Amo Type Original Article
発行日 2016-02
出版物タイトル Acta Medica Okayama
70巻
1号
出版者 Okayama University Medical School
開始ページ 1
終了ページ 12
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26899604
Web of Sience KeyUT 000371288700001
JaLCDOI 10.18926/AMO/53560
フルテキストURL 69_4_237.pdf
著者 Nanba, Shintarou| Ikeda, Fusao| Fujioka, Shin-ichi| Araki, Yasuyuki| Takaguchi, Kouichi| Hashimoto, Noriaki| Seki, Hiroyuki| Takaki, Akinobu| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
抄録 The effectiveness of extending treatment duration as response guided therapy was previously reported for chronic hepatitis C (CHC) genotype 1, but is still controversial for genotype 2. The present study is a retrospective cohort study to investigate the effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for patients with CHC genotype 2 by focusing on the timing at which patients obtained undetectable HCV RNA. A total of 306 patients who obtained undetectable HCV RNA by week 24 of treatment and completed 24 weeks of treatment were enrolled. Rapid virological response (RVR) to standard therapy was achieved by 122 patients (51オ), and 89オ of them obtained sustained virological response (SVR), while 69オ of non-RVR patients achieved SVR. Non-RVR patients with undetectable HCV RNA at week 8, and insufficient adherence<80オ pegylated interferon and ribavirin during the first 24 weeks, significantly improved their SVR rate by extended therapy. Among patients receiving extended therapy, drug adherences did not differ between SVR and non-SVR patients, indicating that extending treatment duration might compensate for insufficient antiviral effects due to insufficient drug adherences. This finding might be useful in creating a guideline for extending treatment duration for patients with CHC genotype 2.
キーワード hepatitis C virus interferon genotype 2 response-guided therapy
Amo Type Original Article
発行日 2015-08
出版物タイトル Acta Medica Okayama
69巻
4号
出版者 Okayama University Medical School
開始ページ 237
終了ページ 244
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26289915
Web of Sience KeyUT 000365519100007
著者 Shoji, Bon| Ikeda, Fusao| Fujioka, Shin-ichi| Kobashi, Haruhiko| Yasunaka, Tetsuya| Miyake, Yasuhiro| Shiraha, Hidenori| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
発行日 2010-11
出版物タイトル Journal of Gastroenterology
45巻
11号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/52790
フルテキストURL 68_4_243.pdf
著者 Wada, Nozomu| Yasunaka, Tetsuya| Ikeda, Fusao| Nishina, Sohji| Korenaga, Masaaki| Hino, Keisuke| Fujioka, Shin-ichi| Osawa, Toshiya| Itoshima, Tatsuya| Kawanaka, Miwa| Yamada, Gotaro| Kariyama, Kazuya| Takayama, Hiroki| Kubota, Junichi| Morimoto, Yoichi| Mizushima, Takaaki| Yamashita, Haruhiko| Tanioka, Hiroaki| Negoro, Yuji| Toshimori, Junichi| Kobashi, Haruhiko| Hirano, Atsushi| Itano, Yasuo| Takaki, Akinobu| Yamamoto, Kazuhide|
抄録 Hepatitis B virus (HBV) is one of the major viruses causing acute hepatitis. Recently, the incidence of acute hepatitis with genotype A has been increasing in Japan. The aim of this study was to investigate acute hepatitis B (AHB) in Okayama prefecture, with special attention to HBV genotype A. AHB patients who visited one of 12 general hospitals in Okayama prefecture between 2006 and 2010 were retrospectively analyzed. Over the course of the study period, 128 patients were diagnosed with AHB. Sexual transmission was supposed in the majority of patients (78 patients, 61%), including 59 (76%) having sex with heterosexual partners. The genotypes of HBV were assessed in 90 patients (70%), of whom 27 patients were infected with genotype A, 5 with genotype B, and 58 with genotype C. The prevalence of genotype A was significantly higher among male patients (28.7%), aged 20-29 (35.6%, p<0.01), among men who had sex with men (100%, p<0.005), and among patients having sex with unspecified partners (44.8%, p<0.005). Genotype A was not a significant factor associated with delayed HBsAg disappearance. Caution should be exercised with regard to sexually transmissible diseases in order to slow the pandemic spread of AHB due to genotype A.
キーワード acute hepatitis hepatitis B virus
Amo Type Original Article
発行日 2014-08
出版物タイトル Acta Medica Okayama
68巻
4号
出版者 Okayama University Medical School
開始ページ 243
終了ページ 247
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 25145410
Web of Sience KeyUT 000340687500006
著者 Kubota, Junichi| Ikeda, Fusao| Terada, Ryo| Kobashi, Haruhiko| Fujioka, Shin-ichi| Okamoto, Ryoichi| Baba, Shinsuke| Morimoto, Youichi| Ando, Masaharu| Makino, Yasuhiro| Taniguchi, Hideaki| Yasunaka, Tetsuya| Miyake, Yasuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
発行日 2009-09
出版物タイトル Journal of Gastroenterology
44巻
9号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/32825
フルテキストURL fulltext.pdf
著者 Nakajima, Hirofumi| Shimomura, Hiroyuki| Iwasaki, Yoshiaki| Ikeda, Fusao| Umeoka, Fumi| Chengyu, Piao| Taniguchi, Hideaki| Ohnishi, Yasuhiro| Takagi, Shin-jiro| Fujioka, Shin-ichi| Shiratori, Yasushi|
抄録 <p>To improve the efficacy of interferon (IFN) treatment for chronic hepatitis C, we have proposed the twice-daily administration of IFN-beta as a promising induction therapy. In this study, we demonstrated differences between the clearance of circulating HCV-RNA and the induction of anti-viral actions during the first 2 weeks of treatment. Nine patients with a high viral load and genotype 1b were randomly assigned to 3 groups: group A received 3MU of IFN-beta twice a day at intervals of 5 and 19 h; group B received 3MU of IFN-beta twice a day at intervals of 10 and 14 h; group C received 6MU of IFN-alpha once a day with ribavirin. The expression of OAS2, PKR, and MxA in peripheral blood mononuclear cells (PBMCs) were quantified by real-time polymerase chain reaction method. The viral clearance showed a bi-phasic pattern, and those in the second phase of groups A and B were significantly steeper than that of group C. The peak level of OAS2 during the first phase was correlated with the first phase decay. The MxA expression tended to be higher in group A and B than in group C. The expression of these 3 proteins tended to decrease at day 6 in group C, but increase in groups A and B. These might make differences in the viral decay during the second phase</p>
キーワード chronic hepatitis C(CHC) interferon(IFN)beta hepatitis C virus(HCV)dynamics antiviral actions real time PCR
Amo Type Article
発行日 2003-10
出版物タイトル Acta Medica Okayama
57巻
5号
出版者 Okayama University Medical School
開始ページ 217
終了ページ 225
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 14679399
Web of Sience KeyUT 000186186000002
JaLCDOI 10.18926/AMO/32110
フルテキストURL fulltext.pdf
著者 Shinji, Toshiyuki| Kyaw, Yi Yi| Gokan, Katsunori| Tanaka, Yasuhito| Ochi, Koji| Kusano, Nobuchika| Mizushima, Takaaki| Fujioka, Shin-ichi| Shiraha, Hidenori| Lwin, Aye Aye| Shiratori, Yasushi| Mizokami, Masashi| Khin, Myo| Miyahara, Masayuki| Okada, Shigeru| Koide, Norio|
抄録 The prevalence of hepatitis C virus (HCV) genotypes in Myanmar in comparison with the rest of Southeast Asia is not well known. Serum samples were obtained from 201 HCV antibody-positive volunteer blood donors in and around the Myanmar city of Yangon. Of these, the antibody titers of 101 samples were checked by serial dilution using HCV antibody PA test II and Terasaki microplate as a low-cost method. To compare antibody titers by this method and RNA identification, we also checked HCV-RNA using the Amplicor 2.0 test. Most high-titer groups were positive for HCV-RNA. Of the 201 samples, 110 were successfully polymerase chain reaction (PCR) amplified. Among them, 35 (31.8%) were of genotype 1, 52 (47.3%) were of genotype 3, and 23 (20.9%) were of type 6 variants, and phylogenetic analysis of these type 6 variants revealed that 3 new type 6 subgroups exist in Myanmar. We named the subgroups M6-1, M6-2, and M6-3. M6-1 and M6-2 were relatively close to types 8 and 9, respectively. M6-3, though only found in one sample, was a brand-new subgroup. These subtypes were not seen in Vietnam, where type 6 group variants are widely spread. These findings may be useful for analyzing how and when these subgroups were formed.
キーワード hepatitis C virus(HCV)genotype type 6 variant Myanmar Southeast Asia phylogenetic analysis
Amo Type Article
発行日 2004-06
出版物タイトル Acta Medica Okayama
58巻
3号
出版者 Okayama University Medical School
開始ページ 135
終了ページ 142
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 15471435
Web of Sience KeyUT 000222273300004
JaLCDOI 10.18926/AMO/31989
フルテキストURL fulltext.pdf
著者 Ishii, Yasushi| Shimomura, Hiroyuki| Ito, Mamoru| Miyake, Masanobu| Ikeda, Fusao| Miyake, Jiro| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Tsuji, Hideyuki| Tsuji, Takao|
抄録 <p>It has been documented that the serum complement activities measured by hemolytic assay (CH50) are decreased after storage of sera at a low temperature in some patients with chronic hepatitis C. However, the mechanism of this phenomenon has not been identified yet. Here, we tried to elucidate factors involved in the cold activation of complement (CAC). To clarify what pathway is activated in CAC, we measured complement cleavage products after cold storage of sera. C4d increased significantly after 12 h-storage at cold temperatures in 5 CAC (+) sera compared with 5 CAC (-) (P &#60; 0.01) and 3 control sera (P &#60; 0.05), while Bb did not increase in any of the groups. In order to determine whether IgG or IgG complex is necessary for CAC, 8 CAC (+) sera were incubated with Protein G Sepharose gel beads, and all of them retained hemolytic activities to some extent after cold storage. Column chromatography through Superose 6HR of CAC-positive serum identified the fractions containing molecules that induced CAC in normal serum, which were depleted by treatment with protein G Sepharose. In conclusion, CAC in hepatitis C seems to occur via a classical or lectin pathway, and the IgG complex produced in hepatitis C virus infection may be an important factor in inducing CAC, a common extrahepatic manifestation of hepatitis C.</p>
キーワード hepatitis C virus chronic hepatitis complement activation
Amo Type Article
発行日 2001-08
出版物タイトル Acta Medica Okayama
55巻
4号
出版者 Okayama University Medical School
開始ページ 229
終了ページ 235
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 11512565
Web of Sience KeyUT 000170367200005
JaLCDOI 10.18926/AMO/31969
フルテキストURL fulltext.pdf
著者 Piao, Cheng-Yu| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Fujio, Kozo| Kaneyoshi, Toshihiko| Araki, Yasuyuki| Hashimoto, Kuniaki| Senoh, Tomonori| Terada, Ryo| Nishida, Tomohiro| Kobashi, Haruhiko| Sakaguchi, Kohsaku| Shiratori, Yasushi|
抄録 <p>Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established. This study was conducted to evaluate the outcomes of lamivudine treatment for patients with HCC using an untreated, matched control group. Thirty patients with controlled HCC orally received lamivudine. As controls, 40 patients with HCC who were not treated with lamivudine and matched for clinical features were selected. The lamivudine-treated and untreated groups were compared with respect to changes in liver function, HCC recurrence, survival, and cause of death. In the lamivudine-treated group, there was significant improvement in the Child-Pugh score at 24 months after starting treatment, while no improvement was observed in the untreated group. There was no significant difference in the cumulative incidence of HCC recurrence and survival between the groups. However, there was a significant difference in the cumulative incidence of death due to liver failure (P= 0.043). A significant improvement in liver function was achieved by lamivudine treatment, even in patients with HCC. These results suggest that lamivudine treatment for patients with HCC may prevent death due to liver failure. Further prospective randomized studies using a larger number of patients are required.</p>
キーワード liver failure Child-Pughscore recurrence survival resistant mutant
Amo Type Article
発行日 2005-10
出版物タイトル Acta Medica Okayama
59巻
5号
出版者 Okayama University Medical School
開始ページ 217
終了ページ 224
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16286955
Web of Sience KeyUT 000232835600006
JaLCDOI 10.18926/AMO/31685
フルテキストURL fulltext.pdf
著者 Kondo, Junichi| Shimomura, Hiroyuki| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Takagi, Shinjiro| Ohnishi, Yasuhiro| Tsuji, Hideyuki| Sakaguchi, Kosaku| Yamamoto, Kazuhide| Tsuji, Takao|
抄録 <p>The preS2 region of the hepatitis B virus (HBV) has been reported to have human polymerized albumin receptor (PAR) activity, which correlates with viral replication. Here, we studied the genomic sequence of the preS region from rare patients lacking PAR activity, despite active viral replication. PAR and DNA polymerase activity was identified in 178 HBe antigen-positive HBV carriers, and a significant correlation between 2 markers was shown, except in 2 hepatitis patients lacking PAR activity. Nucleotide sequences of the preS region of HBV from both patients were examined by direct sequencing of PCR products. In one patient, a 45-base deletion was found to overlap half of the putative polymerized human albumin binding site in the preS2 region. In the other patient, a point mutation at the first nucleotide of the start codon of the preS2 region of HBV was found. There was no such genomic change in the 3 control HBV sequences. These results indicate that the preS2 region is necessary for binding of polymerized human albumin, and this is the first report of naturally existing mutant virus with no or low PAR activity.</p>
キーワード hepatitis B virus preS region polymerized albumin receptor genetic mutation genetic deletion
Amo Type Article
発行日 2002-08
出版物タイトル Acta Medica Okayama
56巻
4号
出版者 Okayama University Medical School
開始ページ 193
終了ページ 198
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 12199524
Web of Sience KeyUT 000177382600004
JaLCDOI 10.18926/AMO/31311
フルテキストURL fulltext.pdf
著者 Tsuji, Hideyuki| Shimomura, Hiroyuki| Fujio, Kozo| Wato, Masaki| Kondo, Junichi| Hasui, Toshimi| Ishi, Yasushi| Fujioka, Shin-ichi| Tsuji, Takao|
抄録 <p>To evaluate viral interference between hepatitis B and C, we studied coinfected patients serologically and molecular biologically. Twenty-seven patients positive for hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus (HCV) antibody, were classified into Groups BC-L and BC-H according to DNA-polymerase activity (less or greater than 100 cpm, respectively). Patients with hepatitis B or C alone were also enrolled as controls. HCV-RNA was detected more often in Group BC-L than in Group BC-H. Genotype 1b of HCV was determined in 75% of Group BC-H, 87.5% of Group BC-L, and 70.7% of hepatitis C-only patients. Activity of DNA-polymerase in coinfected patients was lower in patients positive for HCV-RNA as compared with those negative. HBsAg titers tended to be lower in coinfected patients than in patients with hepatitis B virus (HBV) alone. In conclusion, in coinfection, HBV may suppress the replication of HCV and HCV appears to reduce the expression of HBsAg and probably suppresses HBV replication.&#60;/P&#62;</p>
キーワード hepatitis B virus hepatitis C virus double infection hepatitis B surface antigen hepatitis C virusRNA
Amo Type Article
発行日 1998-04
出版物タイトル Acta Medica Okayama
52巻
2号
出版者 Okayama University Medical School
開始ページ 113
終了ページ 118
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 9588227
Web of Sience KeyUT 000073363000007
JaLCDOI 10.18926/AMO/30729
フルテキストURL fulltext.pdf
著者 Ohta, Takeyuki| Sakaguchi, Kohsaku| Fujiwara, Akiko| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Makino, Yasuhiro| Araki, Yasuyuki| Shiratori, Yasushi|
抄録 <p>This study was conducted to develop a simple surrogate index comprised of routinely available laboratory tests to reflect the histological fibrosis stage. Clinical characteristics and laboratory data from 368 and 249 consecutive patients with chronic hepatitis C, a training cohort and a validation cohort, respectively, were retrospectively evaluated. Platelet (Plt) count and albumin (Alb) level contributed to the discrimination of the respective fibrosis stages. We derived the fi brosis index (FI), FI = 8.0-0.01 x Plt (10 multiply 3/microliter) - Alb (g/dl), from a multiple regression model. FI significantly correlated with the histological fibrosis stage in both the initial and validation cohort at p=0.691 and p=0.661, respectively (Spearman's rank correlation coefficient, p&#60;0.0001). The sensitivity and positive predictive value of FI at a cutoff value &#60; 2.10 for predicting fibrosis stage F0-1 were 66.8% and 78.8% in the initial cohort and 68.5% and 63.6% in the validation cohort, respectively. Corresponding values of FI at a cutoff value &#62;- 3.30 for the prediction of F4 were 67.7% and 75.0% in the initial cohort and 70.8% and 81.0% in the validation cohort. The fibrosis index comprised of platelet count and albumin level reflected the histological fibrosis stage in patients with chronic hepatitis C.</p>
キーワード albumin level chronic hepatitis C fi brosis index fi brosis stage platelet count
Amo Type Article
発行日 2006-04
出版物タイトル Acta Medica Okayama
60巻
2号
出版者 Okayama University Medical School
開始ページ 77
終了ページ 84
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16680183
Web of Sience KeyUT 000237001900002
JaLCDOI 10.18926/AMO/30506
フルテキストURL fulltext.pdf
著者 Wato, Masaki| Shimomura, Hiroyuki| Fujio, Kozo| Tsuji, Hideyuki| Kondo, Junichi| Fujioka, Shin-ichi| Ishii, Yasushi| Hada, Hajime| Tsuji, Takao|
抄録 <p>We purified an apurinic/apyrimidinic (AP) endonuclease from mouse ascites sarcoma (SR-C3H/He) cells. The enzyme showed nicking activity on acid-depurinated DNA but not on untreated, intact DNA. It also showed priming activity for DNA polymerase on both acid-depurinated and bleomycin-damaged DNA. The priming activity on bleomycin-damaged DNA was two times higher than that on an acid-depurinated DNA. The enzymatic properties indicate that the enzyme is a class II AP endonuclease having DNA 3' repair diesterase activity. The purified enzyme has a molecular weight of 39,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The optimal pH for AP endonuclease activity was 8.0 in 50 mM Tris-HCl buffer. The AP endonuclease activity depended on divalent cation such as Mg2+ and Co2+ ions, and was inhibited by 2 mM EDTA with no addition of the divalent cation. An appropriate concentration of sodium or potassium salt stimulated the activity. Partial digestion of the AP endonuclease with Staphylococcus aureus V8 protease produced 4 major peptide fragments which may be used for protein sequencing.</p>
キーワード hepatitis C ultracentrifugation immune complex interferon
Amo Type Article
発行日 1996-06
出版物タイトル Acta Medica Okayama
50巻
3号
出版者 Okayama University Medical School
開始ページ 139
終了ページ 144
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 8805852
Web of Sience KeyUT A1996UU60400004